Page last updated: 2024-08-21

pyrazines and Shingles

pyrazines has been researched along with Shingles in 21 studies

Research

Studies (21)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	10 (47.62)	29.6817
2010's	10 (47.62)	24.3611
2020's	1 (4.76)	2.80

Authors

Authors	Studies
Feng, YF; Li, G; Sun, YQ; Wei, XF; Yang, WH; Zhang, QK	1
Hata, T; Li, C; Two, AM	1
Fujihara, S; Imataki, O; Kirizume, K; Ohnishi, H; Ohue, Y; Shintani, T; Waki, F	1
Anderson, KC; Ben-Yehuda, D; Chanan-Khan, A; Facon, T; Goldschmidt, H; Harousseau, JL; Lonial, S; Neuwirth, R; Reece, D; Richardson, PG; Schuster, MW; Sonneveld, P; Stadtmauer, EA	1
Do, YR; Joo, YD; Kim, BS; Kim, H; Kim, HJ; Kim, I; Kim, K; Kim, SJ; Kwon, JH; Lee, HJ; Lee, JH; Lee, NR; Lee, WS; Nam, SH; Shin, HJ; Sohn, SK; Suh, C; Won, JH; Yoon, SS	1
Allen, S; Mehta, J; Singhal, S; Vickrey, E	1
Adam, Z; Buchler, T; Buresova, L; Hajek, R; Krejci, M; Krivanova, A; Pour, L; Sandecka, V; Vorlicek, J; Zahradova, L	1
Birner, A; Boral, A; Diener, JG; Esseltine, DL; Ghobrial, IM; Ioakimidis, L; Keogh, GP; Matous, J; Mattern, J; Myers, TJ; Nelson, M; Patterson, CJ; Sheehy, P; Soumerai, JD; Treon, SP; Willen, M	1
Chou, T; Hasegawa, Y; Hirose, T; Imai, Y; Ishiguro, T; Kawahara, F; Nagai, H	1
Alexandrescu, DT; Dasanu, CA	1
Heider, U; Kaiser, M; Kleeberg, L; Rademacher, J; Sezer, O; von Metzler, I	1
Bae, SH; Do, YR; Kim, K; Kim, SJ; Lee, JJ; Yang, DH	1
Aoki, T; Imahashi, N; Kitamura, K; Nishiyama, T	1
Guo, H; Mao, J; Qian, X; Sun, C; Sun, H	1
Bergamo, S; di Meo, N; Dondas, A; Trevisan, G	1
Bacovsky, J; Langova, K; Minarik, J; Pika, T; Scudla, V	1
Fujita, Y; Fukushima, T; Iwao, H; Kawanami, T; Masaki, Y; Miki, M; Motoo, Y; Nakajima, A; Nakajima, H; Nakamura, T; Okazaki, T; Sakai, T; Sato, T; Sawaki, T; Tanaka, M; Umehara, H	1
Bernstein, SH; de Vos, S; Esseltine, DL; Fisher, RI; Goy, A; Morrison, VA; Neuwirth, R; Solh, M	1
Lokhorst, HM; Sonneveld, P; van Wieringen, W; Vellenga, E; Wu, KL; Zweegman, S	1
Atanackovic, D; Ayuk, F; Kröger, N; Renges, H; Schieder, H; Zabelina, T; Zander, A	1
Borroni, G; Corso, A; Lazzarino, M; Mangiacavalli, S; Rosso, R; Varettoni, M; Vassallo, C; Zappasodi, P	1

Trials

4 trial(s) available for pyrazines and Shingles

Article	Year
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-10, Volume: 26, Issue:29 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Herpes Zoster; Humans; Multiple Myeloma; Pyrazines; Recurrence; Virus Activation	2008
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-10, Volume: 27, Issue:23 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Viscosity; Bone Marrow Neoplasms; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematocrit; Herpes Zoster; Humans; Immunoglobulin M; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Count; Pyrazines; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia	2009
Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. Haematologica, 2005, Volume: 90, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Herpes Zoster; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Time Factors; Treatment Outcome	2005
Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Experimental hematology, 2006, Volume: 34, Issue:6 Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; CD3 Complex; Chronic Disease; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Herpes Zoster; Humans; Leukopenia; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Remission Induction; Stem Cell Transplantation; Thrombocytopenia; Transplantation, Homologous	2006

Other Studies

17 other study(ies) available for pyrazines and Shingles

Article	Year
[Analysis of Risk Factors of Herpes Zoster in Patients with Multiple Myeloma Treated with Bortezomib]. Zhongguo shi yan xue ye xue za zhi, 2020, Volume: 28, Issue:6 Topics: Boronic Acids; Bortezomib; Herpes Zoster; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors	2020
A case of eosinophilic dermatosis of hematologic malignancy in a patient with multiple myeloma. Dermatology online journal, 2014, Jan-15, Volume: 20, Issue:1 Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Eosinophilia; Herpes Simplex; Herpes Zoster; Humans; Insect Bites and Stings; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Paraneoplastic Syndromes; Pemphigoid, Bullous; Pyrazines; Skin Diseases	2014
[Aggravated post-herpetic neuralgia due to bortezomib]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2008, Volume: 49, Issue:5 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Neuralgia, Postherpetic; Protease Inhibitors; Pyrazines; Recurrence	2008
Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clinical lymphoma & myeloma, 2008, Volume: 8, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies	2008
Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer, 2009, Jan-01, Volume: 115, Issue:1 Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Herpes Zoster; Herpesvirus 3, Human; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Virus Activation	2009
Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:2 Topics: Acyclovir; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Virus Activation	2009
[Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:6 Topics: Acyclovir; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Retrospective Studies	2009
Prophylactic antivirals may be helpful in prevention of varicella-zoster virus reactivation in myeloma, but are they safe? Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2010, Volume: 16, Issue:4 Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Drug Monitoring; Herpes Zoster; Herpesvirus 3, Human; Humans; Incidence; Multiple Myeloma; Neurotoxicity Syndromes; Pyrazines; Renal Insufficiency; Virus Activation	2010
Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib. Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:2 Topics: Acyclovir; Boronic Acids; Bortezomib; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Multiple Myeloma; Pyrazines; T-Lymphocytes	2010
Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:3 Topics: Acyclovir; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome	2011
Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:7 Topics: Acyclovir; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Secondary Prevention; Treatment Outcome	2011
Varicella-zoster virus prophylaxis with the traditional Chinese medicine Radix isatidis (Banlangen) in patients with multiple myeloma treated with bortezomib. Journal of alternative and complementary medicine (New York, N.Y.), 2011, Volume: 17, Issue:11 Topics: Adult; Aged; Antibiotic Prophylaxis; Boronic Acids; Bortezomib; Drugs, Chinese Herbal; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Isatis; Male; Middle Aged; Multiple Myeloma; Phytotherapy; Plant Roots; Pyrazines	2011
Bortezomib and bilateral herpes zoster. Acta dermatovenerologica Alpina, Pannonica, et Adriatica, 2012, Volume: 21, Issue:1 Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Multiple Myeloma; Pyrazines; Virus Activation	2012
Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. British journal of haematology, 2012, Volume: 159, Issue:1 Topics: Acyclovir; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies	2012
Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib. Anticancer research, 2012, Volume: 32, Issue:12 Topics: Acyclovir; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Valacyclovir; Valine; Virus Activation	2012
Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials. Leukemia & lymphoma, 2013, Volume: 54, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Herpes Zoster; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Pyrazines; Recurrence; Risk Factors	2013
Late onset of bortezomib-associated cutaneous reaction following herpes zoster. Annals of hematology, 2007, Volume: 86, Issue:4 Topics: Acyclovir; Anti-Inflammatory Agents; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Dexamethasone; Exanthema; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Skin; Treatment Outcome	2007